Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 4/2018

01-04-2018 | Letter to the Editor

No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer

Authors: Peter B. Østergren, Tobias Wirenfeldt Klausen, Mikkel Fode

Published in: World Journal of Urology | Issue 4/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628CrossRefPubMed
2.
Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525PubMed
3.
Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi:10.​1016/​j.​juro.​2016.​12.​003 (Epub ahead of print) PubMed
4.
Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46CrossRefPubMedPubMedCentral
5.
O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251CrossRefPubMed
Metadata
Title
No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer
Authors
Peter B. Østergren
Tobias Wirenfeldt Klausen
Mikkel Fode
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 4/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2012-x

Other articles of this Issue 4/2018

World Journal of Urology 4/2018 Go to the issue

Original Article

A prospective study evaluating indirect MRI-signs for the prediction of extraprostatic disease in patients with prostate cancer: tumor volume, tumor contact length and tumor apparent diffusion coefficient

Topic Paper

Three dimensional models in uro-oncology: a future built with additive fabrication

Letter to the Editor

Reply to letter to editor regarding: LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer

Topic Paper

Prostatic artery embolization for benign prostatic obstruction: assessment of safety and efficacy

Original Article

Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?

Topic Paper

Robotic surgery in public hospitals of Latin-America: a castle of sand?